Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and adult toys.
Popular Articles

Bingaman, Wyden Among Key Health Reform Lawmakers In The News
Newspapers highlight a few of the key congressional players in the health care debate.
buy viagra
Classification Methods For Identifying The Neural Characterics Of Antidepressant Treatment
Depression is a major public health problem, and one of the most important challenges for psychiatrists is to determine whether an individual with depression should receive cognitive-behavioral therapy or treatment with antidepressant medication. A study by researchers from Emory University, presented at the Annual Meeting of the Organization for Human Brain Mapping in San Francisco, used brain imaging along with sophisticated statistical techniques to examine the differences in brain function that result from these two different kinds of treatment. Forty individuals with depression were scanned with magnetic resonance imaging after undergoing cognitive behavioral therapy or antidepressant therapy. The researchers found that they could distinguish the brain activity of individuals undergoing the two different treatments, and in particular that the two treatments differently affected the communication of the brain areas that are thought to play a role in depression, including the communication between the prefrontal cortex and the nucleus accumbens, and between the subgenual cingulate and the thalamus. The results provide a basis for future research that will try to predict which individuals will benefit from different treatments for depression.
News of the day
Researchers Profile Gene Activity In Acutely Ill Idiopathic Pulmonary Fibrosis Patients
New research may help doctors pinpoint when patients with idiopathic pulmonary fibrosis (IPF) are becoming dangerously ill. The findings may also point the way to interventions that could sustain the lives of IPF patients until life-saving transplants could be performed.
Health Insurance

Unisense FertiliTech A/S Receives CE Mark Of Approval For EmbryoScope(TM) Embryo Monitoring System

Unisense FertiliTech A/S announces that the EmbryoScope(TM) Embryo Monitoring System and EmbryoSlide(TM) tray have received CE approval as class IIa medical devices for use in IVF. Unisense Fertilitech A/S also received the DS/EN ISO13485:2003 and AC:2007 quality system certificate for production, installation and servicing of IVF incubators and related accessories. Francesca Bahr, sales manager at Unisense FertiliTech A/S says, "the CE mark will allow us to market the instrument to Assisted Reproduction clinics across Europe, with the goal of improving embryo assessment and to facilitate the goal of elective single embryo transfer." During IVF treatment, multiple oocytes are removed from the patient and fertilized in-vitro. The resulting fertilized eggs are cultured for a period of 2 to 5 days, before the embryologist must select the best potential embryo or embryos to transfer to the patient. Ideally, a single embryo resulting in a single pregnancy is optimal as multiple pregnancies present risks to maternal and fetal health. A major challenge for the embryologist is determining which embryos have the best potential to create a single healthy baby. The EmbryoScope(TM) Monitoring System allows uninterrupted observation of embryo development in a stable environment. Embryo quality parameters can be assessed and reviewed without the potentially damaging effects of removing the embryo from a controlled incubation environment. Retrospective analysis of development will allow embryologists to identify potentially new parameters for embryo analysis. Mette Munch, Director of regulatory affairs at Unisense FertiliTech A/S says she will now set her goal on FDA 510K clearance in order to facilitate marketing to clinics in the United States. The Announcement of the CE mark coincided with the successful sales launch of the EmbryoScope(TM) Embryo Monitoring System at the European society of Human reproduction and Embryology in Amsterdam, June 29.July 1 2009 Unisense Fertilitech A/S is a Danish company which was founded in 2003, as a daughter company of Unisense A/S. The company develops and manufactures instruments and analysis solutions to facilitate in-vitro Fertilization. The company is currently involved in various international research projects involving embryo selection and analysis, embryo respiration and stem cell research. Unisense FertiliTech A/S


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009